Cai (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Laboratory Findings
T lymphocyte (1 unit increase vs. Not applicable)
Virus clearance
Hazard ratio: 1.002 (1.000-1.005) Adjusted model


Non-randomized clinical trial

Primary data collection


laboratory-confirmed COVID-19 patients

56 patients with laboratory-confirmed COVID-19 were screened, of which 35 were eligible for the FPV arm of the study. A total of 91 laboratory-confirmed COVID-19 patients who had started treatment with LPV/RTV between 24 January and 30 January 2020 were screened, of which 45 were eligible for the control arm of this study.


14 Day

Virus clearance


A multivariate Cox regression model was used to explore the independent factors affecting viral clearance. The time of viral clearance was set as the TIME variable, viral clearance (0 = no, 1 = yes) was set as the status, and the variables that were significant (P < 0.10) in the univariate Cox analysis or were professionally significant (including age, and whether underlying diseases were present or not) were set as independent variable

Laboratory Findings

T lymphocyte

T lymphocyte count

Not applicable

1 unit increase

Hazard ratio

1.002 (1.000-1.005)




WBC. Hp, PLT, Neutrophils, T lymphocyte count , CD8+ T lymphocyte , Time from onset to treatment , FPV versus LPV/RTV , Age , Underlying diseases